Title:
Evidence that PKCα inhibition in Dalton's Lymphoma cells augments cell cycle arrest and mitochondrial-dependent apoptosis

dc.contributor.authorRishi Kant Singh
dc.contributor.authorPraveen Kumar Verma
dc.contributor.authorSandeep Kumar
dc.contributor.authorAlok Shukla
dc.contributor.authorNaveen Kumar
dc.contributor.authorSanjay Kumar
dc.contributor.authorArbind Acharya
dc.date.accessioned2026-02-07T11:05:12Z
dc.date.issued2022
dc.description.abstractProtein kinase Cα (PKCα), belonging to ser/thr protein kinase, perform various biological functions. Overexpression of PKCα has been observed in multiple human malignancies including lymphoma. However, the molecular pathogenesis and involvement of PKCα in Non-Hodgkin lymphoma (NHL) are not clearly understood. Hence, deciphering the role of PKCα in NHL management may provide a better therapeutic option. In the present study, we used selective pharmacological inhibitors Gö6976 and Ro320432 that potentially inhibit PKCα-mediated signaling in DL cells, resulting in the inhibition of cell growth and mitochondrial-dependent apoptosis. PKCα inhibition by these inhibitors also displays cell cycle arrest at the G1 phase and causes growth retardation of DL cells. Our results extended the mechanism of PKCα in NHL, and provided potential implications for its therapy. © 2022 Elsevier Ltd
dc.identifier.doi10.1016/j.leukres.2021.106772
dc.identifier.issn1452126
dc.identifier.urihttps://doi.org/10.1016/j.leukres.2021.106772
dc.identifier.urihttps://dl.bhu.ac.in/bhuir/handle/123456789/41867
dc.publisherElsevier Ltd
dc.subjectApoptosis
dc.subjectCell cycle
dc.subjectDalton's Lymphoma cells
dc.subjectNon-Hodgkin lymphoma
dc.subjectProtein kinase C-α
dc.titleEvidence that PKCα inhibition in Dalton's Lymphoma cells augments cell cycle arrest and mitochondrial-dependent apoptosis
dc.typePublication
dspace.entity.typeArticle

Files

Collections